Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

Blood Cancer J. 2017 Feb 3;7(2):e524. doi: 10.1038/bcj.2017.5.

Authors

M Montillo¹, S O'Brien², A Tedeschi¹, J C Byrd³, C Dearden⁴, D Gill⁵, J R Brown⁶, J C Barrientos⁷, S P Mulligan⁸, R R Furman⁹, F Cymbalista¹⁰, C Plascencia¹¹, S Chang¹¹, E Hsu¹¹, D F James¹¹, P Hillmen¹²

Affiliations

¹ Niguarda Cancer Center, Milano, Italy.
² MD Anderson Cancer Center, Houston, TX, USA.
³ The Ohio State University Medical Center, Columbus, OH, USA.
⁴ The Royal Marsden Hospital, London, UK.
⁵ Princess Alexandra Hospital, Brisbane, QLD, Australia.
⁶ Dana-Farber Cancer Institute, Boston, MA, USA.
⁷ Hofstra Northwell School of Medicine, Hempstead, NY, USA.
⁸ Royal North Shore Hospital, Sydney, NSW, Australia.
⁹ Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA.
¹⁰ Hôpital Avicenne, Paris, France.
¹¹ Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
¹² The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Anemia, Hemolytic, Autoimmune / etiology*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase III as Topic
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Piperidines
Purpura, Thrombocytopenic, Idiopathic / etiology*
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Randomized Controlled Trials as Topic
Retrospective Studies
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine
ofatumumab